{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:44:07Z","timestamp":1768571047301,"version":"3.49.0"},"posted":{"date-parts":[[2025,10,27]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":41,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>The resurgence of monkeypox virus (MPXV) outbreaks has increased demand for validated serological assays to assess exposure and immunity. Cross-reactivity among orthopoxivuses, stemming from high sequence conservation, complicates distinguishing antibody responses from natural MPXV infection versus vaccination or other orthopoxvirus exposures. We validated the Meso Scale Discovery (MSD) V-PLEX Orthopoxvirus Panel 1 (IgG) Kit, which quantifies antibody levels to five MPXV antigens and their vaccina virus (VACV) orthologs, following Good Clinical Laboratory Practice (GCLP) guidelines. We assessed assay performance using serum from 26 individuals with prior mpox, 52 JYNNEOS vaccine recipients, and 179 unexposed controls. The assay reliably detected antibody responses in all exposed cohorts with peak levels observed 2-months post-vaccination. Antibody levels to specific antigens also correlated with Modified Vaccinia Ankara (MVA) neutralization titer, particularly for MPXV B6R\/VACV B5R, MPXV E8L\/VACV D8L, and MPXV M1R\/VACV L1. Receiver operating characteristic (ROC) analysis showed that some individual antigens achieved high sensitivity and specificity for exposure detection (AUC &gt; 0.96 for VACV D8L, MPXV B6R, VACV B5R); however, individual antigens performed poorly in distinguishing infection from vaccination. In contrast, antibody level ratios between some MPXV and VACV orthologs effectively differentiated MPXV infection from vaccinia vaccination with high sensitivity and specificity (e.g. MPXV A35R\/VACV A33R ortholog ratio, AUC = 0.97, sensitivity = 0.97, specificity = 0.96). Our findings validate the MSD assay for clinical research and serosurveillance to assess MPXV immunity and support the utility of ortholog pair ratio analysis as a strategy to discriminate vaccinated and infected individuals.<\/jats:p>\n                <jats:sec>\n                  <jats:title>Importance<\/jats:title>\n                  <jats:p>Mpox continues to spread around the world, with recent data showing increasing incidence in the United States. While there are multiple FDA-authorized real-time PCR tests for diagnostic use, there are no FDA-authorized serological tests and few laboratory-developed serological tests offered. We evaluated the Meso Scale Discovery V-PLEX Orthopoxvirus Panel 1 (IgG) Kit according to Good Clinical Laboratory Practice guidelines and found that assay reliably detected antibody responses in mpox and vaccinia exposed cohorts and could distinguish them from unexposed cohorts. Intriguingly, we found that antibody level ratios between certain MPXV and VACV orthologs could distinguish prior mpox infection from vaccinia vaccination. Overall, these data highlight the use of multi-antigen panels in challenging scenarios for serological testing such as the cross-reactivity presented by orthopoxviruses.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.10.24.25338410","type":"posted-content","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:10:28Z","timestamp":1761577828000},"source":"Crossref","is-referenced-by-count":0,"title":["Differentiating Mpox Infection and Vaccination Using a Validated Multiplex Orthopoxvirus IgG Serology Assay"],"prefix":"10.64898","author":[{"given":"Jonathan C.","family":"Reed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Downs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaden","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarice","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"McClurkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Holzhauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane A.","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chase A.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara M.","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Golden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Koelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-0527","authenticated-orcid":false,"given":"Alexander L.","family":"Greninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025102913550594000_2025.10.24.25338410v1.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.21091"},{"key":"2025102913550594000_2025.10.24.25338410v1.2","unstructured":"Wilkin TJ , Team AAS . 2025. Tecovirimat Is Safe but Not Efficacious in People with Clade II MpoxConference on Retroviruses and Opportunistic Infections (CROI). San Francisco, California."},{"key":"2025102913550594000_2025.10.24.25338410v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2412439"},{"key":"2025102913550594000_2025.10.24.25338410v1.4","unstructured":"European Medicines Agency. 2022. EMA recommends approval of Imvanex for the prevention of monkeypox disease."},{"key":"2025102913550594000_2025.10.24.25338410v1.5","unstructured":"U.S. Food and Drug Administration. 2019. JYNNEOS \u2013 Smallpox and Mpox Vaccine, Live, Non-replicating."},{"key":"2025102913550594000_2025.10.24.25338410v1.6","unstructured":"2022-24 Mpox (Monkeypox) Outbreak: Global Trends. https:\/\/worldhealthorg.shinyapps.io\/mpx_global\/#4_Global_situation_update. Retrieved 2 December 2024."},{"key":"2025102913550594000_2025.10.24.25338410v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/nm1273"},{"key":"2025102913550594000_2025.10.24.25338410v1.8","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28429"},{"key":"2025102913550594000_2025.10.24.25338410v1.9","unstructured":"Health C for D and R. 2024. Monkeypox (mpox) and Medical Devices. FDA. FDA. https:\/\/www.fda.gov\/medical-devices\/emergency-situations-medical-devices\/monkeypox-mpox-and-medical-devices. Retrieved 11 December 2024."},{"key":"2025102913550594000_2025.10.24.25338410v1.10","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/v14091960","article-title":"Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus","volume":"14","year":"2022","journal-title":"Viruses"},{"key":"2025102913550594000_2025.10.24.25338410v1.11","doi-asserted-by":"publisher","DOI":"10.3201\/eid1404.071044"},{"key":"2025102913550594000_2025.10.24.25338410v1.12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1089\/vbz.2011.0779","article-title":"Optimization of Peptide-Based ELISA for Serological Diagnostics: A Retrospective Study of Human Monkeypox Infection","volume":"12","year":"2012","journal-title":"Vector Borne Zoonotic Dis"},{"key":"2025102913550594000_2025.10.24.25338410v1.13","doi-asserted-by":"crossref","first-page":"115004","DOI":"10.1016\/j.jviromet.2024.115004","article-title":"Discordant performance of mpox serological assays","volume":"329","year":"2024","journal-title":"J Virol Methods"},{"key":"2025102913550594000_2025.10.24.25338410v1.14","doi-asserted-by":"crossref","unstructured":"Jones S , Hicks B , Callaby H , Bailey D , Gordon NC , Rampling T , Houlihan C , Jones R , Pond M , Mehta R , Wright D , Oeser C , Tonge S , Linley E , Rowe C , Hallis B , Otter A . 2025. Assessment of MpoxPlex, a high-throughput and multiplexed immunoassay: a diagnostic accuracy study. Lancet Microbe 100987.","DOI":"10.1016\/j.lanmic.2024.100987"},{"key":"2025102913550594000_2025.10.24.25338410v1.15","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1038\/s41467-023-41587-x","article-title":"Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals. 1","volume":"14","year":"2023","journal-title":"Nat Commun"},{"key":"2025102913550594000_2025.10.24.25338410v1.16","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1038\/s41467-023-41587-x","article-title":"Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals","volume":"14","year":"2023","journal-title":"Nat Commun"},{"key":"2025102913550594000_2025.10.24.25338410v1.17","doi-asserted-by":"crossref","first-page":"e29134","DOI":"10.1002\/jmv.29134","article-title":"Development of a novel serological assay for the detection of mpox infection in vaccinated populations","volume":"95","year":"2023","journal-title":"J Med Virol"},{"key":"2025102913550594000_2025.10.24.25338410v1.18","doi-asserted-by":"crossref","first-page":"126453","DOI":"10.1016\/j.vaccine.2024.126453","article-title":"Evaluation of a multiplexed immunoassay for assessing long-term humoral immunity Orthopoxviruses","volume":"42","year":"2024","journal-title":"Vaccine"},{"key":"2025102913550594000_2025.10.24.25338410v1.19","doi-asserted-by":"crossref","first-page":"1585284","DOI":"10.3389\/fimmu.2025.1585284","article-title":"Correlation between microneutralization test and a multiplexed immunoassay for evaluation of monkeypox and vaccinia virus antibodies before and after smallpox vaccination","volume":"16","year":"2025","journal-title":"Front Immunol"},{"key":"2025102913550594000_2025.10.24.25338410v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.08.019"},{"key":"2025102913550594000_2025.10.24.25338410v1.21","unstructured":"Landis JT , An H , Bailey AG , Dittmer DP , Marron JS . 2021. dr4pl: Dose Response Data Analysis using the 4 Parameter Logistic (4pl) Model. https:\/\/CRAN.R-project.org\/package=dr4pl."},{"key":"2025102913550594000_2025.10.24.25338410v1.22","unstructured":"Kassambara A. 2023. rstatix: Pipe-Friendly Framework for Basic Statistical Tests. https:\/\/github.com\/kassambara\/rstatix."},{"key":"2025102913550594000_2025.10.24.25338410v1.23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77"},{"key":"2025102913550594000_2025.10.24.25338410v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(92)90535-W"},{"key":"2025102913550594000_2025.10.24.25338410v1.25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.66.12.7217-7224.1992"},{"key":"2025102913550594000_2025.10.24.25338410v1.26","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.70.6.3753-3762.1996"},{"key":"2025102913550594000_2025.10.24.25338410v1.27","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1128\/jvi.62.10.3772-3778.1988","article-title":"Vaccinia virus gene D8 encodes a virion transmembrane protein","volume":"62","year":"1988","journal-title":"J Virol"},{"key":"2025102913550594000_2025.10.24.25338410v1.28","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1128\/jvi.63.10.4285-4291.1989","article-title":"Fatty acid acylation of vaccinia virus proteins","volume":"63","year":"1989","journal-title":"J Virol"},{"key":"2025102913550594000_2025.10.24.25338410v1.29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01524-08"},{"key":"2025102913550594000_2025.10.24.25338410v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2023.05.001"},{"key":"2025102913550594000_2025.10.24.25338410v1.31","first-page":"652","article-title":"Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax","volume":"82","year":"2007","journal-title":"J Virol"},{"key":"2025102913550594000_2025.10.24.25338410v1.32","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.2008\/004440-0"},{"key":"2025102913550594000_2025.10.24.25338410v1.33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042353"},{"key":"2025102913550594000_2025.10.24.25338410v1.34","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(23)00352-3","article-title":"Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study","volume":"23","author":"group P study","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025102913550594000_2025.10.24.25338410v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/nm1457"},{"key":"2025102913550594000_2025.10.24.25338410v1.36","doi-asserted-by":"publisher","DOI":"10.1086\/520936"},{"key":"2025102913550594000_2025.10.24.25338410v1.37","first-page":"2400575","article-title":"Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023","volume":"29","year":"2024","journal-title":"Eurosurveillance"},{"key":"2025102913550594000_2025.10.24.25338410v1.38","first-page":"237","article-title":"Early Release - Short-Lived Neutralizing Antibody Responses to Monkeypox Virus in Smallpox Vaccine\u2013Naive Persons after JYNNEOS Vaccination - Volume 31, Number 2\u2014February 2025 - Emerging Infectious Diseases journal - CDC","volume":"31","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"2025102913550594000_2025.10.24.25338410v1.39","doi-asserted-by":"crossref","first-page":"105622","DOI":"10.1016\/j.ebiom.2025.105622","article-title":"Development and validation of a quantitative Orthopoxvirus immunoassay to evaluate and differentiate serological responses to Mpox infection and vaccination","volume":"113","year":"2025","journal-title":"eBioMedicine"},{"key":"2025102913550594000_2025.10.24.25338410v1.40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40249-025-01280-1","article-title":"Immunogenicity of monkeypox virus surface proteins and cross-reactive antibody responses in vaccinated and infected individuals: implications for vaccine and therapeutic development","volume":"14","year":"2025","journal-title":"Infect Dis Poverty"},{"key":"2025102913550594000_2025.10.24.25338410v1.41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12915-023-01699-8","article-title":"Cross-reactive antibody response to Monkeypox virus surface proteins in a small proportion of individuals with and without Chinese smallpox vaccination history","volume":"21","year":"2023","journal-title":"BMC Biol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.10.24.25338410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:49:34Z","timestamp":1768510174000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.10.24.25338410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1101\/2025.10.24.25338410","relation":{},"subject":[],"published":{"date-parts":[[2025,10,27]]},"subtype":"preprint"}}